Revenue
2019
2020
2021
2022
2023
2024
2025
Vivos Therapeutics, Inc. (VVOS)
Price$0.14375Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M | $13.1M | $11.4M |
| Gross profit | $10.5M | $9.0M | $8.3M | $10.0M | $12.6M | $10.4M | $8.7M |
| Gross margin | 60.44% | 60.00% | 59.93% | 62.52% | 74.65% | 79.70% | 75.99% |
| Research & development | $100,000 | $100,000 | $100,000 | $200,000 | $200,000 | — | — |
| Operating expenses | $30.4M | $20.2M | $25.6M | $35.0M | $33.0M | $22.5M | $19.2M |
| Operating income | −$19.9M | −$11.2M | −$17.3M | −$25.0M | −$20.4M | −$12.0M | −$10.6M |
| Operating margin | −114.05% | −74.32% | −125.32% | −156.21% | −120.71% | −92.15% | −92.84% |
| EBITDA | −$18.6M | −$10.6M | −$16.7M | −$24.4M | −$19.6M | −$11.3M | −$9.8M |
| EBITDA margin | −106.55% | −70.45% | −120.82% | −152.03% | −116.37% | −86.65% | −86.24% |
| Net income | −$21.2M | −$11.1M | −$13.6M | −$23.8M | −$20.3M | −$12.1M | −$10.8M |
| Net profit margin | −121.37% | −74.09% | −98.42% | −148.81% | −120.15% | −92.28% | −94.39% |
| Basic EPSper basic share | -$2.07 | -$2.22 | -$11.14 | -$25.90 | -$24.00 | -$35.00 | -$23.75 |
| Diluted EPSper diluted share | -$2.07 | -$2.22 | -$11.14 | -$25.90 | -$24.00 | -$35.00 | -$23.75 |
Owners
Reported shareholders
≈9.32%of listed shares
V-Co Investors 3 LLC1.35M shares · Mar 31, 2026
View holders
| Holder | % owned |
|---|---|
V-Co Investors 3 LLC | ≈9.32%1.35M shares |
Skaff Michael C | ≈9.24%1.34M shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.58%85K shares |
IHT Wealth Management, LLC | 0.53%76.74K shares |
Huntsman Ronald Kirk | ≈0.50%73.06K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.42%60.63K shares |
COMMONWEALTH EQUITY SERVICES, LLC | 0.29%42.5K shares |
UBS Group AG | 0.27%39.15K shares |
B. Riley Wealth Advisors, Inc. | 0.26%38.07K shares |
Centurion Wealth Management LLC | 0.25%35.68K shares |
BlackRock, Inc. | 0.19%27.82K shares |
STATE STREET CORP | 0.17%24.92K shares |
Sequoia Financial Advisors, LLC | 0.17%24K shares |
VANGUARD FIDUCIARY TRUST CO | 0.16%23.43K shares |
NORTHERN TRUST CORP | 0.14%20.78K shares |
Acorn Wealth Advisors, LLC | 0.10%14.78K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.07%10.08K shares |
Tower Research Capital LLC (TRC) | 0.04%5.21K shares |
JOHNSON GREGG C | ≈0.03%4K shares |
OSAIC HOLDINGS, INC. | <0.01%1.14K shares |
Percentages use 14.53M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 31, 2026Form 4 | V-Co Investors 3 LLC +1TenPercentOwner | BuyCommon Stock · indirect | 308.8K | $1.34 | $413.9K | 1.35M |
| Mar 31, 2026Form 4 | V-Co Investors 3 LLC +1TenPercentOwner | BuyCommon Stock · indirect | 1.04M | $1.34 | $1.40M | 1.04M |
| Mar 31, 2026Form 4 | V-Co Investors 3 LLC +1TenPercentOwner | BuySeries B Common Stock Warrant · derivative · indirect | 1.78M | $1.34 | $2.39M | 1.78M |
| Mar 31, 2026Form 4 | V-Co Investors 3 LLC +1TenPercentOwner | BuySeries A Common Stock Warrant · derivative · indirect | 1.78M | $1.34 | $2.39M | 1.78M |
| Mar 31, 2026Form 4 | V-Co Investors 3 LLC +1TenPercentOwner | BuyPre-Funded Warrant · derivative · indirect | 430.0K | $1.34 | $576.1K | 430.0K |